


# Retinal physiology and therapeutic approaches

## Physiology

### In health

The retina is a layer of tissue less than 0.5 mm thick, that lines the back of the eye.<sup>19</sup> It is broadly split into two layers: the retinal inner surface is attached to the vitreous body, the clear gel that separates the lens and the retina; while its outer surface is attached to Bruch's membrane (Figure 1). When looking at a cross section of the retina as shown in Figure 1, several sub-layers can be identified. The innermost (closest to the vitreous) being the nerve fiber layer and the outermost being the retinal pigmented epithelium (RPE). Each layer of the retina contains a different type of cell. The layers located above the RPE are made of neurons and synapses and is referred to as the neurosensory retina. In the centre of the retina is an oval-shaped pigmented area called the macula that can be seen on photographs of the retina (Figure 2).



**Fig. 1: Anatomy of the eye and the retina. (Left)** Anatomy of the eye with the retina identified. Image credits: Rhcastilhos and Jmarchn, CC BY-SA 3.0, via Wikimedia Commons. **(Right)** The retina and its subdivision into layers. From inner retina to outer retina: inner limiting membrane (ILM), nerve fiber layer (NFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), photoreceptors (PHR), retinal pigmented epithelium (RPE), Bruch's membrane (BrM), choriocapillaris (CC), Sattler's layer (SL), Haler's layer (HL). Modified from the work of Triviño et al., published under CC BY 3.0 license.<sup>47</sup>

The macula is about 5 mm wide and is responsible for the highly detailed, central vision, owing to its high concentration of photoreceptor cells, namely rods and cones. In particular, cones are highly concentrated in the centre of the macula, in a pit approximately 1.5 mm wide named the fovea. The fovea is a critical area of the retina, as this is where visual acuity is highest. It is also the area where a number of pathological conditions are present.

Another important structure of the retina in disease is the optic disc. The optic disc appears as a round spot on fundus photographs of the retina (Figure 2) and is around 1.8 mm wide. Through the optic disc passes the optic nerve, the fibers of which extend to form the nerve fiber layer, which transmits visual information to the brain. The optic nerve is composed of the axons of the retinal ganglion cells, amounting to between 500,000 and 1.2 million, and is surrounded by connective tissue.<sup>39</sup>




Fig. 2: Anatomical features of the healthy retina on a fundus photograph. By Mikael Häggström, used with permission.

Phototransduction, the conversion of light into an electrical signal, results from a cascade of events in the retina. Visual information originates from light hitting the retina. The light crosses the retinal thickness to reach the body of the photoreceptors, in the layer just before the RPE (see Figure 1).

Activation of photoreceptors by photons starts a cascade of biochemical reactions that transforms light into a biochemical signal.<sup>22</sup> This biochemical signal is picked up by cells in the inner layers of the retina, which transform it into an electrical signal.<sup>3</sup> The electrical signal is then transmitted to the nerve fiber layer, which relays it to the brain via the optic nerve, enabling vision.

Owing to its pigmentation, the RPE acts as a buffer for any remaining light, protecting the retina from light damage and preventing backreflection of light that may

interfere with the visual outcome. The RPE is formed of a single layer of epithelial cells, whose primary function is to support photoreceptors. To fulfil this purpose, the RPE acts as the blood-retinal barrier, regulating the transport of ions, fluid, proteins and other molecules.<sup>9</sup>

The photoreceptors are attached to the RPE cells' plasma membrane. Through this close interaction, the RPE collects by-products of the photoreceptors, a washout essential to maintain a healthy neurosensory retina. The RPE also transports nutrients such as retinoids to the cell where they are essential for the production of the light-sensitive rhodospin protein.<sup>9</sup> Those by-products are released into the systemic circulation via the choroid, one of the two circulations of the retina.<sup>9</sup> The cells of the RPE also play a major role in the immune response in the retina and in maintaining the choroidal vasculature through secretion of various vascular growth factors.<sup>9,15</sup>

Visual functions require high metabolic activity from the retinal cells, which makes the retinal tissue very demanding in oxygen. In fact, the rates of oxygen consumption per unit volume of tissue are comparable for the brain and the retina.<sup>30</sup> To sustain the demand in oxygen, the retina is equipped with a dense network of capillaries, that branches out of the central retinal artery (CRA) and finishes at the central retinal vein (CRV). The CRA is a branch of the ophthalmic artery and the CRV drains into the superior ophthalmic vein. Both the CRA and CRV enter and exit the retina along the optic nerve. The CRA's branches spread across four plexi within the inner half of the retinal depth, namely, the superficial vascular plexus (SVP) and the intermediate (ICP), deep (DCP) and the radial peripapillary capillary plexus (RPCP). The terms superficial vascular complex (SVC) and deep vascular complex (DVC) are sometimes used to designate the RPCP-SVP complex and the ICP-DCP complex, respectively. The inner retinal circulation provides oxygen for the inner 60–80 % of the tissue. The perfusion of the remaining outer 20–40 % is covered by the choroid.

The choroid is a vascular tissue of the eye that lies behind the RPE, from which it is separated by Bruch's membrane. Bruch's membrane is a thin (2–4  $\mu\text{m}$ ), permeable barrier that provides structural support to the RPE and regulates gas and mass exchanges with the choroid.<sup>13</sup> The choroid is structured in three vascular layers. From the outermost to the innermost: Haller's layer, Sattler's layer and the choriocapillaris (CC). The diameter of the vessels in each layer decreases as it approaches the retina, with the CC only composed of capillaries. The vascular input to the choroid is provided by the short posterior ciliary arteries (between 6 and 12), which are branches of the ophthalmic artery.<sup>25</sup> The large vessels of the two outer layers of the choroid run parallel to the retinal axis. Some arterioles from Sattler's layer branch at an almost 90° angle to perfuse the CC.<sup>33</sup> Each of these arterioles form an hexagonal-shaped domain, fed by a single arteriole and drained by a varying number of venules back into Sattler's layer.<sup>50</sup> The capillaries of the CC have wide lumen (the cavity delimited by the vessel's walls), between 7–40  $\mu\text{m}$  in the CC against 5–10  $\mu\text{m}$  in the retina, and are arranged into a single

plane, with many connections between adjacent capillaries, also known as anastomosis.<sup>7,11,18</sup> Furthermore, the capillary walls have openings (or fenestrations), increasing their permeability.<sup>33</sup> The fenestrations on the capillary walls are more numerous on the side facing the retina and are at least wide enough to let molecules with a diffusional radius of  $3.7\text{ }\mu\text{m}$  pass into the blood.<sup>33,7</sup> This particular architecture combined with a high blood flow allows the CC to provide enough oxygen through diffusion across Bruch's membrane and the RPE and to clear waste from the retina through the systemic circulation.

The blood supply from the choroid to the outer retina is indirect. Therefore, the choroid has high blood flow and a high oxygen content.<sup>7</sup> The high concentration of oxygen in the choroidal circulation creates a strong gradient for its diffusion between the choriocapillaris and the outer retina. The high blood flow rates may also help regulating the temperature of the macula, by keeping it at the same temperature as the rest of the body.<sup>7,35</sup>

While appropriate blood supply is necessary to maintain vision, blood vessels can interfere with light and hinder resulting images. The distribution of photoreceptors in the retina is heterogeneous, with a higher concentration in the parafovea, for rods, and fovea, for cones.<sup>49</sup> For this reason, the centre of the fovea is an avascular zone around  $500\text{ }\mu\text{m}$  wide, often referred to as the foveolar avascular zone (FAZ).

The interactions between layers of the retina, e.g., the RPE and photoreceptors, is essential for visual function. Disruption of the delicate structure of the retina leads to degeneration of sight.

## In disease

While the retina is a key element for visual function, its relative fragility makes it susceptible to a number of conditions, some of which may lead to blindness. Loss of visual acuity can be caused by failures at any level of the phototransduction cascade.

**Dry age-related macular degeneration.** The dry form of age-related macular degeneration (AMD) is a common condition in individuals over fifty years of age. It is characterised by the presence of accumulated cellular debris under (drusen) and above (reticular pseudo-drusen) the RPE.<sup>8</sup> The drusen and pseudo-drusen appear when accumulated stress from age and other environmental factors such as cigarette smoking and diet cause the dysfunction of the RPE's clearance functions. In the end-stage of dry AMD, RPE cells degenerate and form geographic atrophy in the macula.<sup>23</sup> Geographic atrophy is the name given to patches of atrophied RPE cells that can be seen on fundus photographs. Ultimately sight loss is due to the atrophy of the photoreceptors deprived from the support of underlying RPE cells, but a gradual distortion of images is also present from the early stages.<sup>31,48</sup>

**Retinitis pigmentosa.** Similarly, individuals with retinitis pigmentosa (PR) progressively lose sight from degeneration of the photoreceptors. Disease-related mutations are typically expressed by rods, leading to their degeneration in early stages of PR. For a reason still unclear, cones cell degeneration follows from the absence of rods, despite cones not expressing the mutations responsible for rod death. Multiple hypothesis have been suggested for this phenomenon. One of them is the oxygen toxicity hypothesis. As the choroid lacks the capacity to regulate blood flow accordingly to metabolic needs of the retina, some suggested that the absence of rods leads to high oxygen tension in the photoreceptor layers, an hyperoxia detrimental to cones survival.<sup>38,45</sup> Another hypothesis speculates that cones survival is dependent on a trophic factor provided by rods. Therefore, the later degeneration of cones could be explain by the absence of such factors.<sup>37</sup>

**Diabetic retinopathy.** One of the consequences of diabetes is the degeneration of the smaller vessels in the retina, the capillaries. Such degeneration include an increase in vascular permeability, a loss of the pericytes coating capillary walls and a thickening of the endothelial basement membrane upon which endothelial cells are attached.<sup>29</sup> Additionally, a rarefaction of capillaries can be observed around the foveal avascular zone. Such microvascular degeneration may cause microvascular occlusions, haemorrhages and oedemas as well as macular ischaemia.<sup>29</sup> The subsequent release of vascular endothelial growth factor (VEGF) may progress the diabetic retinopathy (DR) to its proliferative stage. In proliferative DR, elevated VEGF levels cause the growth of abnormal capillary membranes in a process known as neovascularization. The neovascular membranes cause further haemorrhages and oedemas and scaring of the tissue. Scaring and the toxicity of blood damage the photoreceptors, sometimes permanently, resulting in dramatic loss of sight.<sup>17,19</sup> Moreover, the neovasculature may pierce through the inner limiting membrane and haemorrhage in the vitreous or preretinal space, the potential space between the inner limiting membrane and the vitreous, disturbing vision.

**Neovascular age-related macular degeneration** The neovascular form of AMD is characterised by a much more dramatic loss of sight and the appearance of macular neovasculature (MNV). As most cases of neovascular AMD happen in eyes affected by dry AMD, it may be referred to as a late stage of AMD. The current understanding of the pathogenesis of neovascular AMD is that, in addition to other age-related changes in the retina, the progressive buildup of materials in Bruch's membrane characteristic of dry AMD induces hypoxic conditions in the outer retina.<sup>23,31</sup> The subsequent upregulation of VEGF by RPE cells stimulate angiogenesis in the choriocapillaris.<sup>23</sup> The resulting neovasculature may pierce through Bruch's membrane, growing below the RPE, or through the RPE, growing in between the RPE and the photoreceptors, in the subretinal space. The neovasculature may also emerge from the inner retinal circulation. Regard-

less of the location, neovascular membranes are associated with oedema, haemorrhage, scarring and RPE or retinal detachment (when the retina separates from the RPE), all of which cause the quick loss of sight observed in neovascular AMD.<sup>19,23</sup>

**Retinal tears and breaks** Tears may occur in the retina for various reasons, including trauma and surgery. Posterior vitreous detachment is another reason for the apparition of tears and breaks (tears through the whole thickness of the neurosensory retina). With age, the vitreous humor undergoes progressive liquefaction. In addition, there is gradual loss of adhesion between the inner limiting membrane and the posterior vitreous cortex to which it is attached.<sup>8,29</sup> The combination of those two factors facilitates the accumulation of vitreous fluid in the preretinal space, tearing apart the inner limiting membrane and the vitreous. However, in areas of strong adhesion of the inner limiting membrane, the mechanical forces induced by the fluids can cause retinal tears or breaks and macular holes.<sup>41</sup> Macular holes cause blurry vision while retinal tears provide a path to the subretinal space which may fill with fluids, causing retinal detachment.<sup>29</sup> Additionally, the traction caused by the fluid in the preretinal space can cause retinal detachment.

**Retinal vessel occlusion** A number of conditions may cause blood vessels in the retina to clog or collapse. Accumulation of plaque caused by, for example, cholesterol, or a blood clot (embolus) in blood vessels form an obstruction to blood flow.<sup>29</sup> Sick cell retinopathy causes a stiffening of red blood cells which can result in occlusion of arterioles or capillaries, but also of the central retinal artery.<sup>29</sup> Mechanical pressures such as ocular hypertension can cause the collapse of veins, including the central retinal vein, when the external pressure becomes higher than the blood pressure.<sup>20</sup> Stiffening of the central retinal artery is suspected to also compress the central retinal vein.<sup>29</sup> Occlusion of arteries causes non-perfusion areas in the retina, stopping visual functions in the affected areas. Irreversible damage to the retina starts appearing after 100 min of non-perfusion.<sup>20</sup> Some patients with retinal vein occlusion may develop retinal ischaemia, though the reasons are unclear.<sup>24</sup> Other symptoms include retinal oedema and, in some cases, neovascularization in various locations, including the optic disc and the retina.<sup>29</sup>

**Glaucoma** Glaucoma is a group of optic neuropathies affecting the optic nerve and the ganglion cell layer of the retina (see Figure 1). Ophthalmologists observe a thinning of the ganglion cell layer and degeneration of the tissue of the optic nerve. Those symptoms are due to degeneration of the ganglion cell bodies (in the ganglion cell layer) and axons (forming the optic nerve).<sup>36</sup> It is thought that a combination of ocular hypertension and changes in cerebrospinal fluid pressure and retinal blood pressure create a pressure gradient around the optic nerve, increasing mechanical stresses on the tissue.<sup>4,32</sup> Vision loss in glaucoma is due to the loss of connectivity between the retina and

the brain and cannot be recovered.<sup>36</sup>

## Therapeutic strategies

### Surgeries

Retinal detachment often requires emergency surgery to preserve vision. Different methods are available to reconnect the retina with the RPE. One possibility is to insert a so-called scleral buckle in the sclera, the white tissue supporting the eyeball and located behind the choroid in the retina. The scleral buckle will push the sclera towards the detached retina.<sup>42</sup> Another approach consists of pushing the retina towards the RPE. This technique, called pneumatic retinopexi, consists of injecting a gas bubble into the vitreous<sup>42</sup>. The tension created by the gas pushes the retina back into contact with the RPE. Once contact is restored, the RPE can drain the liquid that accumulated in the retinal holes. The gas is naturally removed from the vitreous.

In more complicated cases of retinal detachment, e.g., in the presence of vitreous haemorrhage, vitrectomy might be preferred to pneumatic retinopexi. Vitrectomy consists of replacing the vitreous humour with either a silicone oil substitute or a gas bubble, favouring reattachment in a similar fashion to pneumatic retinopexi.<sup>14</sup> Surgeries for retinal detachment may also be complemented with ILM peeling, cryotherapy or laser photocoagulation. Because the ILM contributes to retinal rigidity and in vitreal traction of the retina, its removal may be useful to facilitate closure of retinal holes and lower the rate of reopening after surgery.<sup>12</sup> Cryotherapy and photocoagulation can be performed to scar the tissue around retinal tears, effectively sealing them to prevent spread that may lead to retinal detachment. Cryotherapy and photocoagulation can be used alone or after pneumatic retinopexi or vitrectomy.<sup>42</sup>

Photocoagulation may also be used to address abnormal neovascularity in diabetic retinopathy or vessel occlusion.<sup>16</sup> The burn induced by the laser therapy to the retinal tissue is aimed to stop further vascular growth by either sealing or ablating the aberrant blood vessels (focal laser photocoagulation) or by ablating in a wider range (panretinal laser treatment). In the case of panretinal laser treatment, it is thought that the damage brought to the retinal tissue causes a change in the oxygen supply and demand balance that could lower VEGF expression.<sup>16</sup> Photodynamic therapy is a similar approach which uses photochemical mechanisms to induce cell death rather than heat which may be preferred for destroying neovascularity in the more fragile foveal region, for example in eyes with neovascular age-related macular degeneration.<sup>40</sup>

In eyes with glaucoma, the aim of surgery is to lower intraocular pressure. This can be done by decreasing the pressure in the aqueous chamber.<sup>36</sup> Laser treatment of the trabecular meshwork, an area of tissue around the base of the cornea (Figure 1), is aimed to improve drainage of the aqueous humor. In some cases, parts of the trabecular meshwork may be removed to allow further drainage in a procedure called trabeculec-

tomy. Conversely, intraocular pressure can be lowered by decreasing the production of aqueous humor, acting on the inflow rather than the outflow of aqueous humor. This treatment, referred to as cyclodiode therapy, aims to reduce this inflow by destroying the ciliary body that produces aqueous humor.<sup>1</sup>

## Drug based

The regulation of intraocular pressure can be achieved with drugs. In fact most patients with glaucoma begin treatment with eye-drops, used daily to reduce intraocular pressure. The eye-drops are designed to lower the aqueous humor production, increase drainage of aqueous humor, or both.<sup>10,36</sup>

Retinal vascular disorders such as neovascular age-related macular degeneration, proliferative diabetic retinopathy or retinal vein occlusion, are for the most part treated with anti vascular growth factors (VEGF).<sup>2,26</sup> These drugs, mostly injected in the vitreous humor, bind to VEGF molecules that drive the growth of immature and leaky blood vessels. Anti-VEGF treatment has proven effective to suppress disease progression, reducing retinal oedema and restoring vision.<sup>2,21,26</sup> Steroids, either oral or intravitreal, can also be prescribed to reduce the production of pro-inflammatory cytokines such as VEGF in order to increase the RPE functions in patients with retinitis pigmentosa presenting macula oedema.<sup>46</sup>

Deterioration of visual functions due to ageing (cellular senescence), whether normal or fasten by disease, has been addressed by a range of therapeutics called senotherapeutics. Their use for this is being investigated as a mean to maintain vision in disease such non-neovascular age-related macular degeneration which lack therapeutic targets.<sup>27</sup>

## Other

Alternative intervention types are possible, however, their use remain rare as they are investigated for efficiency and safety. Retinal prosthesis have started being approved for use in late stages of certain retinal diseases such as retinitis pigmentosa.<sup>28</sup> The artificial retina replaces the degenerated photoreceptors by a video camera.<sup>28,44</sup> The pixelated image is then transferred to the inner retina's neurons, relatively spared by retinitis pigmentosa, using microelectrodes. The transfer of the electrical signal to the brain is then achieved normally through the optic nerve.<sup>28,44</sup>

Because matured RPE and photoreceptor cells are unable to divide and proliferate, stem cell therapy is a promising therapeutic approach in eyes with photoreceptor or RPE atrophy such as age-related macular degeneration.<sup>6,43</sup> Stem cells are naturally found in the body and have yet to form into a specific cell type hence have the ability to form into many different cell types. Therefore, stem cells injected into the retina are



able to replace degenerated RPE or photoreceptor cells and halt loss of vision or even improve vision.<sup>34</sup>

Gene therapy is an intervention that aims to slow the progress of inherited retinal diseases such as retinitis pigmentosa. It consists of introducing copies of healthy genes into the retina in order to reduce degeneration from disease-related mutations.<sup>5</sup> Viruses are designed to safely deliver the healthy genes to cells, which will either replace or silence the mutant genes.<sup>5</sup>

## References

- [1] D. Allbon and J. Meyer. Cyclodiode laser glaucoma therapy. *StatPearls [Internet]. Treasure Island (FL)*, Jan. 2022.
- [2] C. Andreoli and J. Miller. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. *Current Opinion in Ophthalmology*, 18(6):502–508, 11 2007. doi: 10.1097/icu.0b013e3282f0ca54.
- [3] O. E. Arslan. Anatomy and physiology of retina and posterior segment of the eye. In *Drug Delivery for the Retina and Posterior Segment Disease*, pages 3–33. Springer International Publishing, 2018. doi: 10.1007/978-3-319-95807-1\_1.
- [4] L. R. Band, C. L. Hall, G. Richardson, O. E. Jensen, J. H. Siggers, and A. J. E. Foss. Intracellular flow in optic nerve axons: A mechanism for cell death in glaucoma. *Investigative Ophthalmology & Visual Science*, 50(8):3750, aug 2009. doi: 10.1167/iovs.08-2396.
- [5] R. Battu, D. Ratra, and L. Gopal. Newer therapeutic options for inherited retinal diseases: Gene and cell replacement therapy. *Indian Journal of Ophthalmology*, 70(7):2316, 2022. doi: 10.4103/ijo.ijo\_82\_22.
- [6] Á. I. Berta, K. Boesze-Battaglia, S. Genini, O. Goldstein, P. J. O'Brien, Á. Szél, G. M. Acland, W. A. Beltran, and G. D. Aguirre. Photoreceptor cell death, proliferation and formation of hybrid rod/s-cone photoreceptors in the degenerating STK38l mutant retina. *PLoS ONE*, 6(9):e24074, sep 2011. doi: 10.1371/journal.pone.0024074.
- [7] A. Bill, G. Sperber, and K. Ujii. Physiology of the choroidal vascular bed. *International Ophthalmology*, 6(2):101–107, Feb. 1983. doi: 10.1007/bf00127638.
- [8] J. Bottós, J. Elizalde, E. Rodrigues, and M. Maia. Current concepts in vitreomacular traction syndrome. *Current Opinion in Ophthalmology*, 23(3):195–201, Apr. 2012. doi: 10.1097/icu.0b013e328352404c.

- 
- [9] M. Boulton and P. Dayhaw-Barker. The role of the retinal pigment epithelium: Topographical variation and ageing changes. *Eye*, 15(3):384–389, May 2001. doi: 10.1038/eye.2001.141.
  - [10] A. Chakrabarti, N. Mohan, N. Nazm, R. Mehta, and D. Edward. Newer advances in medical management of glaucoma. *Indian Journal of Ophthalmology*, 70(6): 1920, 2022. doi: 10.4103/ijo.ijo\_2239\_21.
  - [11] T. Chan-Ling, M. E. Koina, J. R. McColm, J. E. Dahlstrom, E. Bean, S. Adamson, S. Yun, and L. Baxter. Role of CD44<sup>+</sup> stem cells in mural cell formation in the human choroid: Evidence of vascular instability due to limited pericyte ensheathment. *Investigative Ophthalmology & Visual Science*, 52(1):399, Jan. 2011. doi: 10.1167/iovs.10-5403.
  - [12] I. P. Chatziralli, P. G. Theodossiadis, and D. H. W. Steel. INTERNAL LIMITING MEMBRANE PEELING IN MACULAR HOLE SURGERY; WHY, WHEN, AND HOW? *Retina*, 38(5):870–882, may 2018. doi: 10.1097/iae.0000000000001959.
  - [13] C. A. Curcio and M. Johnson. Structure, function, and pathology of bruch’s membrane. In *Retina*, pages 465–481. Elsevier, 2013. doi: 10.1016/b978-1-4557-0737-9.00020-5.
  - [14] N. Dervenis, P. Dervenis, T. Sandinha, D. C. Murphy, and D. H. Steel. Intraocular tamponade choice with vitrectomy and internal limiting membrane peeling for idiopathic macular hole. *Ophthalmology Retina*, 6(6):457–468, jun 2022. doi: 10.1016/j.oret.2022.01.023.
  - [15] B. Detrick and J. J. Hooks. The RPE cell and the immune system. In *Retinal Pigment Epithelium in Health and Disease*, pages 101–114. Springer International Publishing, 2020. doi: 10.1007/978-3-030-28384-1\_6.
  - [16] J. R. Evans, M. Michelessi, and G. Virgili. Laser photocoagulation for proliferative diabetic retinopathy. *Cochrane Database of Systematic Reviews*, nov 2014. doi: 10.1002/14651858.cd011234.pub2.
  - [17] M. Friedlander. Fibrosis and diseases of the eye. *Journal of Clinical Investigation*, 117(3):576–586, mar 2007. doi: 10.1172/jci31030.
  - [18] A. W. Fryczkowski. Anatomical and functional choroidal lobuli. *International Ophthalmology*, 18(3):131–141, 1994. doi: 10.1007/bf00915961.
  - [19] M. P. Gupta, A. A. Herzlich, T. Sauer, and C.-C. Chan. Retinal anatomy and pathology. In *Developments in Ophthalmology*, pages 7–17. S. Karger AG, Oct. 2015. doi: 10.1159/000431128.

- 
- [20] S. S. Hayreh, M. Zimmerman, M. Beri, and P. Podhajsky. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. *Ophthalmology*, 111(1):133–141, jan 2004. doi: 10.1016/j.ophtha.2003.03.002.
  - [21] J. S. Heier, A. N. Antoszyk, P. R. Pavan, S. R. Leff, P. J. Rosenfeld, T. A. Ciulla, R. F. Dreyer, R. C. Gentile, J. P. Sy, G. Hantsbarger, and N. Shams. Ranibizumab for treatment of neovascular age-related macular degeneration. *Ophthalmology*, 113(4):633–642.e4, apr 2006. doi: 10.1016/j.ophtha.2005.10.052.
  - [22] J. B. Hurley. Phototransduction. In *Encyclopedia of Neuroscience*, pages 687–692. Elsevier, 2009. doi: 10.1016/b978-008045046-9.00914-1.
  - [23] R. D. Jager, W. F. Mieler, and J. W. Miller. Age-related macular degeneration. *New England Journal of Medicine*, 358(24):2606–2617, jun 2008. doi: 10.1056/nejmra0801537.
  - [24] M. Khayat, M. Williams, and N. Lois. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. *Survey of Ophthalmology*, 63(6):816–850, nov 2018. doi: 10.1016/j.survophthal.2018.04.005.
  - [25] J. Kiel. The ocular circulation. *Colloquium Series on Integrated Systems Physiology: From Molecule to Function*, 3(1):1–81, 2010. doi: 10.4199/c00024ed1v01y201012isp012.
  - [26] H. M. Kim and S. J. Woo. Ocular drug delivery to the retina: Current innovations and future perspectives. *Pharmaceutics*, 13(1):108, jan 2021. doi: 10.3390/pharmaceutics13010108.
  - [27] K. S. Lee, S. Lin, D. A. Copland, A. D. Dick, and J. Liu. Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration. *Journal of Neuroinflammation*, 18(1), jan 2021. doi: 10.1186/s12974-021-02088-0.
  - [28] Y. H.-L. Luo and L. da Cruz. The argus® II retinal prosthesis system. *Progress in Retinal and Eye Research*, 50:89–107, jan 2016. doi: 10.1016/j.preteyeres.2015.09.003.
  - [29] C. A. Medina, J. H. Townsend, and A. D. Singh, editors. *Manual of Retinal Diseases*. Springer International Publishing, 2016. doi: 10.1007/978-3-319-20460-4.
  - [30] C. J. Medrano and D. A. Fox. Oxygen consumption in the rat outer and inner retina: Light- and pharmacologically-induced inhibition. *Experimental Eye Research*, 61(3):273–284, Sept. 1995. doi: 10.1016/s0014-4835(05)80122-8.

- 
- [31] R. Newsom and C. Simon. Age-related macular degeneration. *InnovAiT: Education and inspiration for general practice*, 1(10):710–713, oct 2008. doi: 10.1093/innovait/inn130.
  - [32] R. W. Nickells, G. R. Howell, I. Soto, and S. W. M. John. Under pressure: Cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. *Annual Review of Neuroscience*, 35(1):153–179, July 2012. doi: 10.1146/annurev.neuro.051508.135728.
  - [33] D. L. Nickla and J. Wallman. The multifunctional choroid. *Progress in Retinal and Eye Research*, 29(2):144–168, Mar. 2010. doi: 10.1016/j.preteyeres.2009.12.002.
  - [34] H. C. O’Neill, I. J. Limnios, and N. L. Barnett. Advancing a stem cell therapy for age-related macular degeneration. *Current Stem Cell Research & Therapy*, 15(2): 89–97, mar 2020. doi: 10.2174/1574888x15666191218094020.
  - [35] L. M. Parver. Temperature modulating action of choroidal blood flow. *Eye*, 5(2): 181–185, Mar. 1991. doi: 10.1038/eye.1991.32.
  - [36] H. A. Quigley. Glaucoma. *The Lancet*, 377(9774):1367–1377, Apr. 2011. doi: 10.1016/s0140-6736(10)61423-7.
  - [37] P. A. Roberts. Mathematical models of retinitis pigmentosa: The trophic factor hypothesis. *Journal of Theoretical Biology*, 534:110938, Feb. 2022. doi: 10.1016/j.jtbi.2021.110938.
  - [38] P. A. Roberts, E. A. Gaffney, J. P. Whiteley, P. J. Luthert, A. J. E. Foss, and H. M. Byrne. Predictive mathematical models for the spread and treatment of hyperoxia-induced photoreceptor degeneration in retinitis pigmentosa. *Investigative Ophthalmology & Visual Science*, 59(3):1238, Mar. 2018. doi: 10.1167/iovs.17-23177.
  - [39] J. J. Salazar, A. I. Ramírez, R. D. Hoz, E. Salobrar-Garcia, P. Rojas, J. A. Fernández-Albarral, I. López-Cuenca, B. Rojas, A. Triviño, and J. M. Ramírez. Anatomy of the human optic nerve: Structure and function. In *Optic Nerve*. IntechOpen, feb 2019. doi: 10.5772/intechopen.79827.
  - [40] U. Schmidt-Erfurth and T. Hasan. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. *Survey of Ophthalmology*, 45(3):195–214, nov 2000. doi: 10.1016/s0039-6257(00)00158-2.
  - [41] D. L. Shechtman and M. T. Dunbar. The expanding spectrum of vitreomacular traction. *Optometry - Journal of the American Optometric Association*, 80(12): 681–687, dec 2009. doi: 10.1016/j.optm.2009.07.014.

- 
- [42] A. Sodhi, L.-S. Leung, D. V. Do, E. W. Gower, O. D. Schein, and J. T. Handa. Recent trends in the management of rhegmatogenous retinal detachment. *Survey of Ophthalmology*, 53(1):50–67, jan 2008. doi: 10.1016/j.survophthal.2007.10.007.
- [43] J. Stern and S. Temple. Retinal pigment epithelial cell proliferation. *Experimental Biology and Medicine*, 240(8):1079–1086, jun 2015. doi: 10.1177/1535370215587530.
- [44] K. Stingl, R. Schippert, K. U. Bartz-Schmidt, D. Besch, C. L. Cottrill, T. L. Edwards, F. Gekeler, U. Greppmaier, K. Kiel, A. Koitschev, L. Kühlewein, R. E. MacLaren, J. D. Ramsden, J. Roider, A. Rothermel, H. Sachs, G. S. Schröder, J. Tode, N. Troelenberg, and E. Zrenner. Interim results of a multicenter trial with the new electronic subretinal implant alpha AMS in 15 patients blind from inherited retinal degenerations. *Frontiers in Neuroscience*, 11, aug 2017. doi: 10.3389/fnins.2017.00445.
- [45] J. Stone. Mechanisms of photoreceptor death and survival in mammalian retina. *Progress in Retinal and Eye Research*, 18(6):689–735, Nov. 1999. doi: 10.1016/s1350-9462(98)00032-9.
- [46] S. Strong, G. Liew, and M. Michaelides. Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention. *British Journal of Ophthalmology*, 101(1):31–37, dec 2016. doi: 10.1136/bjophthalmol-2016-309376.
- [47] A. Triviño, R. de Hoz, B. Rojas, B. Gallego, A. Ramirez, J. Salazar, and J. Ramirez. Effects of hypercholesterolaemia in the retina. In *Ocular Diseases*. InTech, Sept. 2012. doi: 10.5772/48359.
- [48] D. N. Zacks, A. J. Kocab, J. J. Choi, M. S. Gregory-Ksander, M. Cano, and J. T. Handa. Cell death in AMD: The rationale for targeting fas. *Journal of Clinical Medicine*, 11(3):592, jan 2022. doi: 10.3390/jcm11030592.
- [49] M. A. Zouache. Variability in retinal neuron populations and associated variations in mass transport systems of the retina in health and aging. *Frontiers in Aging Neuroscience*, 14, Feb. 2022. doi: 10.3389/fnagi.2022.778404.
- [50] M. A. Zouache, I. Eames, C. A. Klettner, and P. J. Luthert. Form, shape and function: segmented blood flow in the choriocapillaris. *Scientific Reports*, 6(1), Oct. 2016. doi: 10.1038/srep35754.